Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product. Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.
Last trade$4.88
Day change+$0.11 (+2.31%)
Day range$4.76 – $5.00
Volume68,646
Market cap$60M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$60.49M
Price / earnings
17.22×
Price / book
1.82×
Price / sales
0.34×
EV / sales
0.27×
EV / EBITDA
6.61×
Profitability
Earnings per share
$0.28
Return on assets
5.94%
Return on equity
10.57%
Dividend yield
3.97%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.91×
Quick ratio
1.12×
Cash ratio
0.76×
Cash flow
Price / cash flow
10.46×
Price / free cash flow
30.46×
Free cash flow
$1.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LFVN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q2 FY2026 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q2 FY2025 Dec 31, 2024
Q1 FY2025 Sep 30, 2024
Revenue
$37.12M
$42.38M
$48.93M
$47.56M
$47.56M
$55.11M
$67.76M
$47.21M
Cost of revenue
$9.15M
$9.33M
$12.72M
$9.75M
$9.75M
$11.07M
$13.2M
$9.49M
Gross profit
$27.97M
$33.04M
$36.21M
$37.82M
$37.82M
$44.05M
$54.57M
$37.72M
Selling, general and administrative
$12.73M
$13.87M
$15.83M
$14.85M
$14.85M
$18.68M
$18.61M
$14.85M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$28.11M
$31.38M
$35.72M
$35.55M
$35.55M
$41.9M
$51.14M
$35.15M
Operating income
-$136K
$1.67M
$487K
$2.27M
$2.27M
$2.15M
$3.43M
$2.57M
Interest expense
$45K
$164K
$0
$87K
$0
$431K
$0
$0
Income before taxes
-$184K
$1.7M
$473K
$2.24M
$2.24M
$2.4M
$3.09M
$2.58M
Income taxes
$12K
$417K
$197K
$86K
$86K
$437K
$539K
$752K
Net income
-$196K
$1.28M
$276K
$2.16M
$2.16M
$1.96M
$2.55M
$1.83M
Net income attributable to common shareholders
-$196K
$1.28M
$276K
$2.16M
$2.16M
$1.96M
$2.55M
$1.83M
EBITDA
$594K
$2.36M
$1.24M
$2.88M
$2.88M
$2.9M
$4.23M
$3.37M
Basic earnings per share
-$0.02
$0.10
$0.02
$0.17
$0.17
$0.16
$0.21
$0.15
Diluted earnings per share
-$0.02
$0.10
$0.02
$0.17
$0.17
$0.15
$0.19
$0.14
Recent news
Company coverage with links to the original publishers.
Lifevantage reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03 by 66.67%, but revenues of $37.12 million missed expectations by 3.84%. The company's year-over-year performance declined significantly with EPS down from $0.18 and revenues down from $47.56 million. The stock has underperformed the S&P 500 by 23.1% year-to-date and carries a Zacks Rank #3 (Hold) rating.
McKesson reported quarterly earnings of $11.68 per share, beating consensus estimates of $10.69, representing a 9.26% earnings surprise. The company posted revenues of $110.96 billion, surpassing estimates by 0.77%. McKesson has outperformed the S&P 500 by 11.3% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Dental Supplies industry ranks in the top 39% of Zacks industries.
Pro-Dex (PDEX) reported Q3 earnings of $0.92 per share, beating consensus estimates by 37.31%, with revenues of $20.56 million. The company has outperformed the S&P 500 by 64.2% year-to-date and received a Zacks Rank #1 (Strong Buy) rating. However, the Medical-Dental Supplies industry ranks in the bottom 32% of Zacks industries, which could limit future performance.
Zacks has added three stocks to its Strong Sell list today: Camping World (CWH), LifeVantage (LFVN), and Centerra Gold (CGAU). All three companies have experienced significant downward revisions to their current year earnings estimates over the last 60 days, with CWH and LFVN seeing particularly steep declines of 44.4% and 40% respectively.
LifeVantage Corporation announced that CEO Terrence Moorehead and CFO Carl Aure will participate in the WTR Virtual Insights Conference on September 23, 2026. The webcast presentation will begin at 1:30 p.m. Eastern Time and is open to all investors through the company's Investor Relations website.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.05 per share
Declared
Nov 5, 2026
Ex-dividend
Dec 1, 2026
Pay date
Dec 15, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 1, 2026
$0.05
Sep 15, 2026
recurring
Jun 1, 2026
$0.05
Jun 15, 2026
recurring
Mar 2, 2026
$0.045
Mar 16, 2026
recurring
Dec 1, 2025
$0.045
Dec 15, 2025
recurring
Sep 8, 2025
$0.045
Sep 16, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.